Lindsay A. Md Rosenwald - Jun 1, 2021 Form 4 Insider Report for Fortress Biotech, Inc. (FBIO)

Role
PRESIDENT, CEO & CHAIRMAN, Director, 10%+ Owner
Signature
/s/ Samuel Berry, Attorney-in-Fact
Stock symbol
FBIO
Transactions as of
Jun 1, 2021
Transactions value $
$6,021
Form type
4
Date filed
4/29/2022, 04:22 PM
Previous filing
Apr 6, 2023
Next filing
Jun 11, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FBIO COMMON STOCK, PAR VALUE $0.001 Award $3K +1.3K +0.01% $2.31 10.4M Jun 1, 2021 Direct F1
transaction FBIO COMMON STOCK, PAR VALUE $0.001 Other $0 +8.13K +0.08% $0.00 10.4M Sep 30, 2021 Direct F2
transaction FBIO COMMON STOCK, PAR VALUE $0.001 Other $0 +4.62K +0.04% $0.00 10.4M Nov 16, 2021 Direct F3
transaction FBIO COMMON STOCK, PAR VALUE $0.001 Award $3.03K +1.25K +0.01% $2.42 10.4M Dec 1, 2021 Direct F1
transaction FBIO COMMON STOCK, PAR VALUE $0.001 Award $0 +1.1M +10.58% $0.00 11.5M Jan 1, 2022 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired as purchases made under the Issuer's Employee Stock Purchase Plan ("ESPP") during the ESPP offering period.
F2 The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock.
F3 The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock.
F4 The reporting person was granted 1,102,986 restricted shares pursuant to the issuer's Long-Term Incentive Plan on January 1, 2022.